ArticleBMC cancer2026
Effectiveness, safety, and retreatment outcomes in GEP-NET patients undergoing
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeptide receptor radionuclide therapy (PRRT) using
methodsThis retrospective study included 49 patients treated with
resultsIn the GEP-NET group, the median number of PRRT cycles was 4 with a median cumulative activity of 27.9 GBq. Median OS was 54.2 months (95% CI: 33.2-upper bound not reached), and median PFS was 24.1 months (95% CI: 11.8-36.1). PET-CT-based response assessment was available in 36 of 45 patients. Using evaluable patients as denominator, the exploratory visual SSTR-PET-CT-based objective response rate was 30.6%. Considering the entire initial-treatment cohort and assuming patients without follow-up imaging were non-responders, the ORR was 24.4%. Grade 3 or higher hematologic toxicity occurred in 4.4% of patients with one case each of grade 3 anemia and grade 4 leukopenia while no grade 3 or higher renal toxicity was observed. One patient (2%) developed myelodysplastic syndrome (MDS), followed by acute myeloid leukemia (AML). In the retreatment group (median 4 additional cycles), the median PFS was 18.1 months (95% CI: 8.6-24.6) and the ORR was 30.8% (n = 13). No grade ≥3 toxicities or hematologic malignancies were observed.
conclusionPRRT at our institution showed clinical outcomes and a favorable short-term safety profile broadly consistent with previously published PRRT studies. These findings support the role of PRRT in routine clinical practice. Retreatment outcomes appeared encouraging in selected patients but should be interpreted as exploratory given the limited cohort size, retrospective design, and absence of formal comparative analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.